News & Updates

Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.

For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.

Worsening right ventricular (RV) function normally occurs in patients with heart failure and preserved left ventricular ejection fraction (HFpEF) and, along with its ratio to pulmonary pressure, is predictive of a higher risk of HF hospitalizations and cardiovascular death, reports a study.

A considerable decline of >0.07 m/s in 4-metre gait speed (4MGS) over 6 months is associated with a higher risk of all-cause, nonelective hospitalization or death over the next 6 months in patients with a newly diagnosed idiopathic pulmonary fibrosis (IPF), suggests a study.

Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.

Treatment of gestational diabetes before 20 weeks’ gestation appears to lead to a modestly lower incidence of a composite of adverse neonatal outcomes as compared with no-immediate treatment, with no substantial differences noted for pregnancy-related hypertension or neonatal lean body mass, as reported in a study.

In the treatment of individuals with uncomplicated urinary tract infection (UTI), the use of antibiotics with lower reported resistance rates such as amoxicillin-clavulanate and nitrofurantoin (AC + N) lowers the rate of treatment failure, as shown in a study from Singapore.

Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.